Gilead Shares Early Results Of Remdesivir Trial In COVID-19 Patients

The transcript discusses a study on the drug Remdesivir, which was tested on nearly 600 hospitalized COVID-19 patients with moderate pneumonia. Patients were divided into groups receiving different treatments, including Remdesivir for five or ten days, or standard care alone. The study found that patients treated with Remdesivir for five days showed a 65% improvement in symptoms by the 11th day compared to those receiving standard care. However, the ten-day treatment showed similar results to standard care. No deaths occurred in the five-day treatment group, while some deaths were reported in the other groups. Gilead, the drug's manufacturer, plans to publish the full study results in a medical journal, and the FDA has authorized emergency use of Remdesivir for COVID-19 patients.

What did Gilliad state about the patients who received Ramdev severe for five days?

What is the significance of the FDA's authorization regarding REM death severe?